Zoran Zdraveski
Fortune : 3 504 $ au 31/07/2026
Fortune : 3 504 $ au 31/07/2026
Zoran Zdraveski is currently Secretary, Chief Legal & Strategy Officer at TScan Therapeutics, Inc. since 2021.
Formerly, Dr. Zdraveski was Vice President & Associate General Counsel at Epizyme, Inc. from 2012 to 2017 and Secretary & Chief Legal Officer at Magenta Therapeutics, Inc. from 2017 to 2021.
Education includes undergraduate and graduate degrees from Southern Methodist University, a graduate degree from Suffolk University Law School conferred in 2007, and a doctorate from the Massachusetts Institute of Technology conferred in 2002.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC. 0,01 % | 20/01/2026 | 4 716 ( 0,01 % ) | 3 504 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Conseiller Juridique Général | 09/09/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| MAGENTA THERAPEUTICS | Conseiller Juridique Général | 01/04/2021 |
| EPIZYME, INC. | Corporate Officer/Principal | 01/04/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Southern Methodist University
Southern Methodist University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Suffolk University Law School
Suffolk University Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national